Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Core Insights - Profusa, Inc. is set to present findings from its pilot clinical study on tissue oxygen monitoring in peripheral artery disease (PAD) patients at the Leipzig Interventional Course (LINC) 2026, scheduled for January 27-30, 2026 [1] - The company's Lumee technology allows for continuous, real-time measurement of tissue oxygen, aimed for both clinical and home use, with positive feedback received from the U.S.-based clinical study [2] - Profusa is a digital health company focused on developing tissue-integrated sensors that provide actionable, medical-grade data for personal and medical use, emphasizing affordability and long-lasting biosensors [3] Company Overview - Profusa is based in Berkeley, California, and is led by a team of experienced management and a world-class board of directors [3] - The company aims to deliver a personalized biochemical signature that clinicians can trust, utilizing its intelligent data platform [3] - The trademarks "LUMEE," "PROFUSA," and the PROFUSA logo are registered in multiple regions including the United States, Canada, and the European Union [4]